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Summary The aim of this study was to determine whether a very high-risk group based on presenting characteristics could be identified in
patients with advanced Hodgkin's disease who may benefit from high-dose chemotherapy (HDCT). Between 1975 and 1992, 453 previously
untreated patients aged under 60 years who did not progress in the first 6 months afterthe start of standard chemotherapy had their hospital
notes reviewed. The outcomes analysed were early disease progression (in the 6- to 18-month window following the start of chemotherapy)
and disease progression in the whole of the follow-up period. A Cox regression analysis was used to investigate the combined effects of a
number of presenting characteristics on these outcomes. Despite the presence of factors with significant effects on the relative rate of
progression, the absolute effects in a group identified as having the poorest prognosis were not especially poor. No group could be defined
with a freedom from progression rate of less than 70% over 6-18 months, and the worst prognostic group, which included only 53 patients,
had an overall freedom from progression rate of 57% at 5 years. Fourother reported prognostic indices were evaluated using ourdata set, but
none of the indices was more successful in identifying a very high-risk group. It has not been possible to define a sufficiently high-risk group
of patients with Hodgkin's disease based on presenting characteristics for whom HDCT could be advised as part of primary treatment. The
search for more discriminating prognostic factors identifying vulnerable patients with a high risk of relapse must continue before a role can be
found for HDCT following conventional chemotherapy in patients without disease progression.
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High-dose chemotherapy (HDCT) with autologous stem cell
rescue is increasingly being used to treat patients with advanced
Hodgkin's disease who progress during initial therapy, relapse
within 1 year ofcompleting therapy orwho are in second or subse-
quent relapse having received two or more conventional
chemotherapy regimens (Armitage et al, 1989). Overall, approxi-
mately 40-50% of such patients achieve prolonged progression-
free survival using this approach (Carella et al, 1988; Gribben et
al, 1989; Jagannath et al, 1989; Reece et al, 1991). The role of
HDCT in the initial treatment of advanced Hodgkin's disease is a
question of importance but currently is only felt to be appropriate
in patients who progress during primary treatment. If a high-risk
group, not effectively treated with conventional-dose regimens,
could be identified based on features known at presentation, this
population could be used to define the role of HDCT using a
randomized trial. Low-risk patients are likely to incur a greater
treatment-related morbidity and mortality if they are put into a
HDCT programme but could do well with conventional-dose
therapy alone.
The prognostic factors study reported here was carried out on a
series of consecutive patients newly diagnosed with Hodgkin's
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disease who were entered into the Manchester Lymphoma Group
advanced disease protocols between 1975 and 1992. The objective
was to determine whether a very high-risk group ofpatients could
be identified who might benefit from the use of HDCT during
primary therapy. As HDCT is already recommended for patients
who progress during conventional-dose chemotherapy and is
usually offered only to patients under 60 years old, the analysis
was restricted to patients less than 60 years of age who did not
progress during the first 6 months after starting standard
chemotherapy.
METHODS
Patients and treatment
Data were analysed from 453 patients aged under 60 years with
advanced-stage Hodgkin's disease showing no progression in the
first 6 months after starting primary chemotherapy. Pretreatment
characteristics are listed in Table 1. Staging was based on Ann
Arbor criteria (including the Cotswolds modification, Lister et al,
1989) and resulted from a full history and physical examination,
plainradiography ofthe chest, computerized tomography (CT) scan
of the thorax, abdomen and pelvis, complete blood count, serum
biochemical profile and examination ofabone marrow aspirate and
trephine biopsy. In addition, isotope bone scans, ultrasound scans
and biopsies ofsuspicious lesions were performed when necessary.
Patients were treated with either mustine, vinblastine, procar-
bazine and prednisolone (MVPP) or chlorambucil, vinblastine,
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Table 1
Patient characteristics (n=453)
Sex
Male
Female
Stage
IIA
IIB
IIIA
IIIB
IVA
IVB
Bulk
No
Yes
Mediastinal bulk
No
Yes
Histology
LP
NS
MC
LD
Unclassified
10
80
289
164 a
a 60
28 o
78 CD
102 a 40
80 0
47 0-
118 20
214
239
303
150
51
243
131
13
15
Bone marrow
Negative 338
Positive 26
Not known 89
Treatment
ChlVPP/EVA 139
MVPP 314
Disease progression
6-18 months 52
> 18 months 56
Not yet 307
Dead no progression 38
LP, lymphocyte-predominant; NS, nodular sclerosing; MC, mixed cellularity;
LD, lymphocyte-depleted.
procarbazine, prednisolone, etoposide, vincristine and doxorubicin
(ChlVPP/EVA) hybrid chemotherapy. MVPP was given according
to the dose as described by Nicholson et al (1970) and hybrid
chemotherapy according to that described by Radford et al (1995).
Following reassessment, patients whose disease had responded to
chemotherapy were given radiotherapy to sites ofprevious bulk.
<=N 2-\
III-IV neither bulk nor B (n=88)
-----11 bulk and/or B (n=106)
-III-IV bulk and/or B (n=259)
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Figure 1 Freedom from progression according to disease stage (1l-IV),
systemic (B) symptoms and disease bulk
In the analysis, indicator variables were defined to account for
categorical variables. The method of scoring continuous variables
was assessed using smoothed Martingale residual plots (Therneau
et al, 1990) and modelling using natural cubic regression splines
(Durrleman and Simon, 1989). Proportional hazards were assessed
using Arjas plots (Arjas, 1988), smoothed Schoenfeld residual
plots (Schoenfeld, 1982; Pettitt and Bin Daud, 1990) and also by
fitting separate models to partitions ofthe time axis. The influence
of individual cases on the parameter estimates from the final
model was assessed using index plots of standardized score resid-
uals (Barlow and Prentice, 1988).
There were some missing data forthe prognostic variables under
consideration particularly serum lactate dehydrogenase (LDH, 97
cases missing) and erythrocyte sedimentation rate (ESR, 104 cases
missing). It was not possible to use these two variables in the initial
multivariate analysis but they were reanalysed to determine
whether they added further prognostic information to the final
model in the subsets ofcases with data available for each of these
two variables. The analysis was initially confined to a subset of
405 patients with complete data using multivariate variable selec-
tion models. When illustrating the models and the performance of
otherreported indices, we used the subset ofthe 453 cases that had
complete information on the variables relevant to that index.
Parameters evaluated RESULTS
The variables studied were age, gender, disease stage, systemic (B)
symptoms, histology, mediastinal bulk, disease bulk at other sites,
bone marrow involvement, types oftreatment, haemoglobin, white
cell count, lymphocyte count, platelet count and serum bilirubin,
albumin, alkaline phosphatase and aspartate transaminase.
Statistics
The outcomes analysed were early disease progression (in the 6- to
18-month window following the start of chemotherapy) and
disease progression in the whole of the follow-up period. A Cox
regression analysis was used to investigate the combined effects of
a number ofpresenting characteristics on these outcomes.
Initial analysis of stage, systemic (B) symptoms and
disease bulk
As routine staging delineates patients according to disease stage
(II-IV), systemic (B) symptoms and disease bulk, an initial
analysis was performed on the full cross-classification of these
three features to identify whether a combined variable could be
defined. The outcome analysed was disease progression at any
time after the first 6 months. The regression modelling revealed
that systemic (B) symptoms and disease bulk had similar effects
on prognosis but having both variables did not further increase the
risk. A new variable based on these three presenting characteristics
capturing their prognostic effect was defined and is illustrated in
Figure 1.
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Figure 2 Freedom from early disease progression according to risk groups
Analysis of prognostic factors for patients with early
disease progression
To justify consideration of HDCT in the initial treatment of
Hodgkin's disease, it is necessary to identify patients at high
risk ofearly disease progression following treatment with conven-
tional chemotherapy. For this reason, the initial multivariate
analysis was performed on likelihood ofdisease progression in the
6- to 18-month period following the start of chemotherapy (i.e. in
the 12-month period following the completion of 6 months of
chemotherapy). The analysis also includes the new variable identi-
fied in Figure 1 based on disease stage (II-IV), B symptoms
and disease bulk. Forty-five patients were found to have
progressed during this time period out ofthe 405 cases included in
the analysis.
Using a step-up multivariate analysis, the presence of advanced
stage, tumour bulk, systemic (B) symptoms and low lymphocyte
count were found to be associated with a reduced progression-free
interval. The analysis was repeated using a step-down approach
including all features identified to be significant in univariate
analysis at a nominal level (P = 0.1). Identical features were iden-
tified as in the step-up approach. Goodness-of-fit analyses
performed on the final model did not reveal any marked discrepan-
cies from the model assumptions. This analysis suggested that
patients with stage III-IV disease with tumour bulk and/or
systemic (B) symptoms could be further divided based on low/high
lymphocyte count, with a low lymphocyte count (< 0.6 x 109 1-1)
being associated with a poorer prognosis.
Based on these four adverse presenting characteristics i.e. stage,
tumour bulk, systemic (B) symptoms and lymphocyte count, four
groups could be identified with differing progression-free rates in
the 6- to 18-month period following the start ofchemotherapy. The
risk groups were (1) stage III-IV disease with neither bulk nor B
symptoms, (2) stage II disease with bulk and/or B symptoms, (3)
stage III-IV disease with bulk and/or B symptoms and lymphocyte
count > 0.6 x 109 1-1 and (4) stage III-IV disease with bulk and/or
B symptoms and lymphocyte count < 0.6 x 109 l-1. Figure 2 shows
the Kaplan-Meier estimates for the four risk groups; the freedom
from progression rates at 18 months were 94%, 93%, 86% and
70% respectively. The worst prognostic group, which included 36
patients, had an overall progression-free rate of70%.
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Figure 3 Freedom from progression for all follow-up after 6 months
according to risk groups as defined in Table 2
Analysis of prognostic factors for all patients with
progressive disease after 6 months
As the analysis of patients progressing in the 6- to 18-month
period following chemotherapy was not able to identify a suffi-
ciently high-risk group to justify HDCT, the analysis was
expanded to include the entire follow-up period of the 405 cases.
An additional 48 progressions were noted, making a total of 93
patients with progressive disease. The methods used were identical
to those employed in the previous analysis.
Extending the analysis to include all patient follow-up after 6
months led to the identification of one additional adverse variable,
namely bone marrow involvement. The five pretreatment charac-
teristics found to be significant were tumour stage, tumour bulk,
systemic (B) symptoms, lymphocyte count and bone marrow
involvement. Goodness-of-fit analysis revealed some indication of
a time-dependent effect of lymphocyte count; low lymphocyte
count was associated with early relapse but was not as useful a
predictor in the extended follow-up period. Based on this analysis,
a prognostic index was constructed that was able to identify four
risk groups (see Table 2) with 5-year freedom from progression
rates of 88%, 82%, 74% and 57%. The Kaplan-Meier curves for
the four risk groups are shown in Figure 3. The worst prognostic
group, which included 53 patients, had an overall progression-free
rate of57% at 5 years.
Comparison of data with other reported prognostic
indices
Four other reported prognostic indices (Wagstaff et al, 1988;
Straus et al, 1990; Proctor et al, 1991; Hasenclever et al, 1995)
were evaluated using our data set. The performance of these
indices was analysed separately for the 6- to 18-month period and
the whole of the follow-up period. The prognostic indices exam-
ined are summarized as follows.
1. Straus index (1990). This was derived for progression-free
survival and the index was based on the numberofthe following
adverse features: serum LDH greater than 400 IU 1-1, low
haematocrit, age greater than 45 years, bulky mediastinal
disease, inguinal node or bone marrow involvement. Patients
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with no or only one adverse feature were classified as low risk A
and patients with two or more adverse features were classified 100 . , =
as high risk. As haematocrit was not routinely measured in our
patients, a low haematocrit was replaced with low haemoglobin
(< 12 g dl-1 in men, < 10.5 g dl-1 in women). Cases missing bone a)
marrow assessment were taken as negative. Using the Straus .O
U)
index, the freedom-from-progression rates at 18 months and at co
5 years for the high-risk group based on our data set were 86% 0
and 73% respectively (see Figures 4A and 5A). 20- Low risk (n=201)
2. Hasenclever index (1995). This study assessed prognostic . ___High risk(n_171)
factors for time-to-treatment failure. The high-risk group I0
I
0.0 0.5 1.0 1.5 contained patients with low haemoglobin and (stage IVB B Time (years)
disease and/or serum alkaline phosphatase > 230 IU 1-1). 100. -
Analysis using our data set showed that the freedom-from-
progression rates at 18 months and at 5 years for the high-risk
group were 90% and 73% respectively (seeFigures 4B and5B).
3. Proctor index (1991). The index reported was based on survival 60-
data. Calculation ofthe prognostic index was initially based on X
age, disease stage, haemoglobin and absolute lymphocyte count CD
but this was amended laterto include tumourbulk. Patients with - Low risk (n=380)
an index higher than 0.5 were classified as high risk. Analysis -High risk (n=61)
using our data set showed that the freedom-from-progression ,
rates at 18 months and at 5 years for the high-risk group were 00 0.5 1.0 1.5
83% and 72% respectively (see Figures 4C and SC). C Time (years)
4. Wagstaff index (1988). The index reported here was based on 100 : =
survival in stage IIIB and IV patients only and three prognostic
groups were identified based on age, sex, lymphocyte count and
disease stage. The three groups were: low risk (age less than 45 . 6
years with lymphocyte count > 0.75 x 109 1-1) or (female and 0
stage IIIB disease); high risk, male, stage IV with (age > 45 a) 40
years and/or lymphocyte count < 0.75 x 109 1-') and interme- o
diate risk, the rest. The freedom-from-progression rates at 18 20- Low risk (n=289)
months and at 5 years for the high-risk group were 81% and High risk(n1158)
59% respectively (see Figures 4D andSD). 0.0 0.5 10 1.5
S. Manchester index. This is the index derived from the current D Time (years)
analysis (see Table 2). For simplicity, the first three groups were 100o
classified as a low-risk group. The high-risk group is stage
III-IV with [tumour bulk and/or systemic (B) symptoms] and - 80
(lymphocyte count < 0.6 x 109 1-1 and/or bone marrow involve- a)
ment). The freedom-from-progression rates at 18 months and at
5 years for the high-risk group were 72% and 57% respectively co
(see Figures 4E and SE). C - Low risk (n=348) Low Intrmeiaterisk348 6
The performance of all these indices is illustrated collectively
0- 20 = Intermediate risk(n=61)
in Figure 4 (restricted to the 6- to 18-month window) and Figure - High risk(n=38)
S (all follow-up). The above-reported indices were derived using .0 1.5
a variety of outcome measures and some degradation of their E Time (years)
performance on our data set is therefore to be expected. On the 100-
other hand the performance of the Manchester index presents an -
a) _
Table 2 Manchester index*°
Risk group Defining features
Low Stage III-IV neither tumour bulk nor B symptoms
Low intermediate Stage II (tumour bulk and/or B symptoms)
High intermediate Stage 111-IV (bulk and/or B symptoms) and
lymphocyte count > 0.6 x 109 I-'
High Stage III-IV (bulk and/or B symptoms) and
(lymphocyte count < 0.6 x 109 I-' and/or bone
marrow involvement)
cn
401
0)
L 201 ~Low risk(ni=394)
___ High risk (n=53)
.0 0.5 1.0 1.5
Time (years)
Figure 4 Freedom from early disease progression according to risk groups
using Straus (A), Hasenclever (B), Proctor (C), Wagstaff (D) and Manchester
(E) indices
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Figure 5 Freedom from progression for all follow-up after 6 months
according to risk groups using Straus (A), Hasenclever (B), Proctor (C),
Wagstaff (D) and Manchester (E) indices
overoptimistic picture of its ability to discriminate prognosis as it
is illustrated on essentially the same data from which it was
derived. Nevertheless, none ofthe indices were successful in iden-
tifying a sufficiently poor risk group from initial characterictics.
DISCUSSION
There have been a number ofprognostic studies performed during
the last decade attempting to identify a high-risk group ofpatients
who might benefit from more intensive experimental therapy.
Wagstaff et al (1988), analysing 300 patients with advanced
Hodgkin's disease, found that male patients with stage IV disease
and (aged greater than 45 years and/or lymphocytopenia) had the
worst prognosis, with a survival of 34% at 5 years. Proctor et al
(1991) developed a prognostic index based on disease stage, age,
haemoglobin and absolute lymphocyte count to predict patients
who were likely to die of progressive disease. They found that of
101 patients with an index > 0.5, 60% were dead at 4 years
whereas of 336 patients with an index < 0.5, only 18% were dead
at 4 years. Straus et al (1990) found that characteristics consis-
tently associated with poor prognosis included low haematocrit,
high serum LDH, age 2 45 years, inguinal node involvement,
bulky mediastinal disease and bone marrow involvement. In 13 of
their patients with three or more adverse features, only 20%
survived at 5 years. More recently, Hasenclever et al (1995),
analysing 600 patients with stage IIIB-IV Hodgkin's disease and
aged under 60 years, found that patients with low haemoglobin,
stage IVB disease and elevated serum alkaline phosphatase were
associated with the poorest prognosis.
In this study, we have been unable to define a population of
patients with sufficiently poor prognosis to warrant immediate
high-dose chemotherapy following completion of conventional
therapy for Hodgkin's disease. Our poorest risk group had a
progression-free rate of over 70% at 18 months and 57% at 5
years. We reanalysed our data set using previously reported prog-
nostic indices but none of these provided better discrimination.
Most patients, even in the group with the worst prognostic index,
are long-term survivors following completion of conventional
therapy. Treatment involving HDCT with the attendant risk of
early morbidity/mortality and late effects including the develop-
ment of second malignancy should be avoided until disease
progression has occurred.
Patients experiencing disease progression during primary
conventional-dose chemotherapy have a poor prognosis and
should be considered for improved therapeutic approaches
including HDCT with autologous peripheral blood progenitor cell
rescue. Current practice at the Christie Hospital is to carry out
relapse therapy including HDCT when possible in this group and
to consider HDCT for patients with adverse prognostic features at
disease progression.
Until a more powerful index ofprognosis, similar to that estab-
lished for high-grade non-Hodgkin's lymphoma (The International
Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993), can
be found for patients with advanced Hodgkin's disease, HDCT
cannot be recommended as part of the initial treatment of
responding patients because most of these are cured using one of
the standard programmes of combination chemotherapy. In addi-
tion, late relapse (after 12 months) is probably best treated with
conventional-dose chemotherapy (Viviani et al, 1990; Longo et al,
1992), as it is difficult to predict the benefits of HDCT in this
setting in the absence of a randomized trial. The relatively good
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results of second-line chemotherapy in these patients must be
balanced against the risk of procedure-related mortality/morbidity
and the potential late complications of HDCT (especially, second
malignancy, infertility, cardiac and pulmonary dysfunction). For
the moment therefore it appears that HDCT is most appropriate for
patients who have disease progression during initial therapy,
relapse within 12 months of completing therapy or are in second
relapse. Such a strategy limits the toxicity of HDCT to those most
in danger ofprogressive Hodgkin's disease and minimizes the risk
of over-treating patients who are curable using conventional
salvage therapy.
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